CA2742242C - Treatment of pediatric acute lymphoblastic leukemia with a cd19xcd3 bispecific single chain antibody - Google Patents

Treatment of pediatric acute lymphoblastic leukemia with a cd19xcd3 bispecific single chain antibody Download PDF

Info

Publication number
CA2742242C
CA2742242C CA2742242A CA2742242A CA2742242C CA 2742242 C CA2742242 C CA 2742242C CA 2742242 A CA2742242 A CA 2742242A CA 2742242 A CA2742242 A CA 2742242A CA 2742242 C CA2742242 C CA 2742242C
Authority
CA
Canada
Prior art keywords
single chain
pediatric
chain antibody
bispecific single
cd19xcd3 bispecific
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2742242A
Other languages
English (en)
French (fr)
Other versions
CA2742242A1 (en
Inventor
Gerhard Zugmaier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Research Munich GmbH
Original Assignee
Amgen Research Munich GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Research Munich GmbH filed Critical Amgen Research Munich GmbH
Publication of CA2742242A1 publication Critical patent/CA2742242A1/en
Application granted granted Critical
Publication of CA2742242C publication Critical patent/CA2742242C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CA2742242A 2008-11-07 2009-11-06 Treatment of pediatric acute lymphoblastic leukemia with a cd19xcd3 bispecific single chain antibody Active CA2742242C (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US11232308P 2008-11-07 2008-11-07
US61/112,323 2008-11-07
US18329109P 2009-06-02 2009-06-02
US61/183,291 2009-06-02
US22126909P 2009-06-29 2009-06-29
US61/221,269 2009-06-29
PCT/EP2009/007969 WO2010052013A1 (en) 2008-11-07 2009-11-06 Treatment of pediatric acute lymphoblastic leukemia

Publications (2)

Publication Number Publication Date
CA2742242A1 CA2742242A1 (en) 2010-05-14
CA2742242C true CA2742242C (en) 2023-01-10

Family

ID=41796119

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2742242A Active CA2742242C (en) 2008-11-07 2009-11-06 Treatment of pediatric acute lymphoblastic leukemia with a cd19xcd3 bispecific single chain antibody

Country Status (27)

Country Link
US (2) US20110262440A1 (enExample)
EP (4) EP3330293B1 (enExample)
JP (2) JP5798036B2 (enExample)
KR (1) KR101695329B1 (enExample)
CN (2) CN102209729B (enExample)
AU (1) AU2009313039B2 (enExample)
BR (1) BRPI0921341A2 (enExample)
CA (1) CA2742242C (enExample)
CY (3) CY1116160T1 (enExample)
DK (3) DK2344539T3 (enExample)
ES (3) ES2662929T3 (enExample)
HK (1) HK1255590B (enExample)
HR (3) HRP20150400T1 (enExample)
HU (3) HUE025452T2 (enExample)
IL (1) IL212651A (enExample)
LT (2) LT3330293T (enExample)
MX (1) MX2011002931A (enExample)
NO (1) NO2918604T3 (enExample)
NZ (1) NZ591312A (enExample)
PL (3) PL2344539T3 (enExample)
PT (3) PT3330293T (enExample)
RS (3) RS59348B1 (enExample)
RU (3) RU2536933C2 (enExample)
SG (1) SG195549A1 (enExample)
SI (3) SI3330293T1 (enExample)
SM (3) SMT201900546T1 (enExample)
WO (1) WO2010052013A1 (enExample)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6358588A (ja) * 1986-08-29 1988-03-14 Toshiba Corp バ−コ−ド読取装置
DE10254601A1 (de) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
JP5798036B2 (ja) * 2008-11-07 2015-10-21 アムゲン リサーチ （ミュンヘン） ゲーエムベーハー 小児急性リンパ芽球性白血病の新規治療
EP3517961B1 (en) * 2009-01-09 2020-12-30 Oxford BioMedica (UK) Limited Factors
US20150231241A1 (en) * 2012-08-14 2015-08-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
IL282953B2 (en) * 2012-11-13 2026-02-01 Tron Translationale Onkologie An Der Johannes Gutenberg Univ Mainz Gemeinnutzige Gmbh Agents for the treatment of claudin-expressing cancers
TWI682941B (zh) 2013-02-01 2020-01-21 美商再生元醫藥公司 含嵌合恆定區之抗體
CN103131777A (zh) * 2013-02-05 2013-06-05 南京艾迪康医学检验所有限公司 用于检测e2a-pbx融合基因相对表达量的试剂盒
EP3105252B1 (en) 2014-02-12 2019-07-24 Michael Uhlin Bispecific antibodies for use in stem cell transplantation
TWI754319B (zh) 2014-03-19 2022-02-01 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
SI3149480T1 (sl) 2014-05-30 2019-05-31 Amgen Research (Munich) Gmbh Stratifikacija tveganj pri bolnikih z akutno limfoblastno levkemijo prekurzorjev b
US20170252364A1 (en) 2014-07-30 2017-09-07 Mor Research Applications Ltd. Compositions for treatment of acute lymphoblastic leukemia and methods of use thereof
US20170239294A1 (en) * 2014-10-15 2017-08-24 Novartis Ag Compositions and methods for treating b-lymphoid malignancies
ES2809455T3 (es) 2014-11-17 2021-03-04 Regeneron Pharma Métodos para tratamiento tumoral usando anticuerpo biespecífico CD3xCD20
AU2016215110A1 (en) 2015-02-05 2017-09-21 Stc.Unm Anti-pre-BCR antagonists and methods
DK3277725T3 (da) 2015-03-30 2021-01-11 Regeneron Pharma Konstante tungkædeområder med reduceret binding til FC-gammareceptorer
PL3280729T3 (pl) 2015-04-08 2022-08-22 Novartis Ag Terapie cd20, terapie cd22 i terapie skojarzone komórką eksprymującą chimeryczny receptor antygenowy (car) cd19
SI3298042T1 (sl) 2015-05-20 2025-03-31 Amgen Research (Munich) Gmbh Deplecija B celic kot diagnostični marker
MY195059A (en) 2015-09-23 2023-01-05 Regeneron Pharma Optimized Anti-CD3 Bispecific Antibodies and Uses Thereof
CN108602889A (zh) * 2015-12-22 2018-09-28 瑞泽恩制药公司 医治急性成淋巴细胞性白血病的双特异性抗cd20/抗cd3抗体
GB201602974D0 (en) * 2016-02-19 2016-04-06 Clube Jasper R Engineered cells & methods (1)
EP3430052A2 (en) * 2016-03-14 2019-01-23 Millennium Pharmaceuticals, Inc. Method of preventing graft versus host disease
WO2017214207A2 (en) * 2016-06-06 2017-12-14 Juno Therapeutics, Inc. Methods for the treatment of b cell malignancies using adoptive cell therapy
US11590167B2 (en) 2016-12-03 2023-02-28 Juno Therapeutic, Inc. Methods and compositions for use of therapeutic T cells in combination with kinase inhibitors
MA48763A (fr) * 2017-05-05 2020-04-08 Amgen Inc Composition pharmaceutique comprenant des constructions d'anticorps bispécifiques pour un stockage et une administration améliorés
IL327498A (en) 2017-06-02 2026-05-01 Juno Therapeutics Inc Articles of manufacture and methods for treatment using adoptive cell therapy
WO2019089858A2 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Methods of assessing or monitoring a response to a cell therapy
KR102083481B1 (ko) 2018-03-22 2020-03-02 강원대학교산학협력단 아연-키토산 나노 입자를 포함한 급성 림프구성 백혈병 치료용 약학조성물
ES3009025T3 (en) 2018-08-31 2025-03-25 Regeneron Pharma Dosing strategy that mitigates cytokine release syndrome for cd3/cd20 bispecific antibodies
AU2020214336B2 (en) * 2019-01-30 2026-06-04 The Wistar Institute Of Anatomy And Biology DNA-encoded bispecific T-cell engagers targeting cancer antigens and methods of use in cancer theraputics
JP7137696B2 (ja) 2019-05-14 2022-09-14 プロヴェンション・バイオ・インコーポレイテッド １型糖尿病を予防するための方法および組成物
AU2020279224B2 (en) 2019-05-21 2024-12-05 Novartis Ag Trispecific binding molecules against BCMA and uses thereof
UY38701A (es) 2019-05-21 2020-12-31 Novartis Ag Moléculas de unión a cd19, conjugados, composiciones que las comprenden y usos de las mismas
JP6881658B2 (ja) 2019-07-05 2021-06-02 小野薬品工業株式会社 Ｐｄ−１／ｃｄ３二重特異性タンパク質による血液がん治療
KR20230092863A (ko) 2020-06-11 2023-06-26 프로벤션 바이오, 인코포레이티드 제1형 당뇨병을 예방하기 위한 방법 및 조성물
MX2023009433A (es) 2021-02-16 2023-11-29 Children´S Health Care D/B/A/ Children´S Minnesota Metodos para el tratamiento de b-all mediante la administracion de un antagonista del complejo pre-bcr.
MX2023013851A (es) 2021-05-24 2023-12-08 Provention Bio Inc Metodos para el tratamiento de diabetes tipo 1.
KR20240099263A (ko) 2021-10-15 2024-06-28 암젠 리서치 (뮌헨) 게엠베하 Cd19 결합 t 세포 관여 항체의 피하 투여
US12698512B2 (en) 2023-11-06 2026-08-04 City Of Hope Methods comprising oncolytic viruses expressing CD19T and bispecific T cell engagers
AU2024406222A1 (en) 2023-12-20 2026-06-04 Bristol-Myers Squibb Company Antibodies targeting il-18 receptor beta (il-18rβ) and related methods
WO2025250648A1 (en) * 2024-05-28 2025-12-04 Ohio State Innovation Foundation Methods and compositions comprising tagless blinatumomab
WO2026072671A1 (en) 2024-09-24 2026-04-02 City Of Hope Methods comprising oncolytic viruses expressing bcmat and bcma-targeted therapies

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4119397A (en) * 1996-08-28 1998-03-19 Viva Diagnostika Diagnostische Produkte Gmbh Novel combination preparations and their use in immunodiagnosis and immunotherapy
CA2326389C (en) 1998-04-21 2007-01-23 Micromet Gesellschaft Fur Biomedizinische Forschung Mbh Novel cd19xcd3 specific polypeptides and uses thereof
AU2004242846A1 (en) * 2003-05-31 2004-12-09 Micromet Ag Pharmaceutical compositions comprising bispecific anti-CD3, anti-CD19 antibody constructs for the treatment of B-cell related disorders
US8076459B2 (en) * 2003-10-16 2011-12-13 Micromet Ag Multispecfic deimmunized CD3-binders
US8007796B2 (en) * 2005-12-16 2011-08-30 Micromet Ag Means and methods for the treatment of tumorous diseases
RS53263B (sr) * 2006-08-14 2014-08-29 Xencor Inc. Optimizovana antitela usmerena na cd19
EP2352763B2 (en) * 2008-10-01 2022-09-21 Amgen Research (Munich) GmbH Bispecific single chain antibodies with specificity for high molecular weight target antigens
JP5798036B2 (ja) * 2008-11-07 2015-10-21 アムゲン リサーチ （ミュンヘン） ゲーエムベーハー 小児急性リンパ芽球性白血病の新規治療
RU2538965C2 (ru) * 2009-01-19 2015-01-10 Эббви Инк. Вызывающие апоптоз средства для лечения рака и иммунных и аутоиммунных заболеваний
NZ616828A (en) * 2009-01-19 2015-03-27 Abbvie Inc Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US8486933B2 (en) * 2009-05-27 2013-07-16 Abbvie Inc. Pyrimidine inhibitors of kinase activity
KR20120085781A (ko) * 2009-09-20 2012-08-01 아보트 러보러터리즈 Ｂｃｌ-２ 단백질 관련 질환을 치료하는데 사용하기 위한 ａｂｔ-２６３ 결정 형태 및 용매화물
NZ598732A (en) * 2009-10-27 2014-09-26 Amgen Res Munich Gmbh Dosage regimen for administering a cd19xcd3 bispecific antibody

Also Published As

Publication number Publication date
HUE036922T2 (hu) 2018-08-28
PT3330293T (pt) 2019-10-18
CN102209729A (zh) 2011-10-05
RS59348B1 (sr) 2019-10-31
CY1122428T1 (el) 2021-01-27
PL3330293T3 (pl) 2020-02-28
RU2677324C2 (ru) 2019-01-16
HRP20180426T1 (hr) 2018-04-20
RU2018144313A (ru) 2020-06-15
SI3330293T1 (sl) 2019-10-30
DK2918604T3 (en) 2018-03-19
CA2742242A1 (en) 2010-05-14
PT2344539E (pt) 2015-04-01
RU2736802C2 (ru) 2020-11-20
EP2344539A1 (en) 2011-07-20
DK3330293T3 (da) 2019-10-07
HUE025452T2 (en) 2016-05-30
ES2535257T3 (es) 2015-05-07
CN102209729B (zh) 2016-05-25
CY1116160T1 (el) 2017-02-08
PL2918604T3 (pl) 2018-05-30
AU2009313039A1 (en) 2010-05-14
EP3330293B1 (en) 2019-07-24
HUE046222T2 (hu) 2020-02-28
SI2918604T1 (en) 2018-04-30
JP2012508163A (ja) 2012-04-05
US20230235053A1 (en) 2023-07-27
EP2918604B1 (en) 2017-12-20
RS53980B1 (sr) 2015-10-30
NZ591312A (en) 2012-09-28
SMT201800149T1 (it) 2018-05-02
KR101695329B1 (ko) 2017-01-23
WO2010052013A1 (en) 2010-05-14
BRPI0921341A2 (pt) 2016-04-26
ES2662929T3 (es) 2018-04-10
US20110262440A1 (en) 2011-10-27
AU2009313039B2 (en) 2015-06-18
HRP20191715T1 (hr) 2019-12-13
SG195549A1 (en) 2013-12-30
IL212651A (en) 2015-03-31
EP2918604A1 (en) 2015-09-16
JP2015232023A (ja) 2015-12-24
CY1120022T1 (el) 2018-12-12
HK1255590B (en) 2020-07-10
RU2014141180A (ru) 2016-05-10
RS56989B1 (sr) 2018-05-31
LT3330293T (lt) 2019-10-10
NO2918604T3 (enExample) 2018-05-19
HK1215258A1 (en) 2016-08-19
SMT201900546T1 (it) 2019-11-13
MX2011002931A (es) 2011-04-11
RU2014141180A3 (enExample) 2018-06-09
CN106390114A (zh) 2017-02-15
HK1158667A1 (en) 2012-07-20
ES2748126T3 (es) 2020-03-13
EP3330293A1 (en) 2018-06-06
RU2018144313A3 (enExample) 2020-06-15
HRP20150400T1 (hr) 2015-05-08
PL2344539T3 (pl) 2015-07-31
LT2918604T (lt) 2018-03-26
DK2344539T3 (en) 2015-05-04
KR20110091669A (ko) 2011-08-12
PT2918604T (pt) 2018-03-02
EP2344539B1 (en) 2015-02-11
RU2536933C2 (ru) 2014-12-27
IL212651A0 (en) 2011-07-31
EP3594237A1 (en) 2020-01-15
SI2344539T1 (sl) 2015-06-30
SMT201500104B (it) 2015-07-09
JP5798036B2 (ja) 2015-10-21
JP6130451B2 (ja) 2017-05-17
RU2011122827A (ru) 2012-12-20

Similar Documents

Publication Publication Date Title
US20230235053A1 (en) Treatment of pediatric acute lymphoblastic leukemia
HK1255590A1 (en) Treatment of pediatric acute lymphoblastic leukemia with bispecific antibodies against cd3xcd19
US20240109964A1 (en) Treatment of acute lymphoblastic leukemia
HK40022438A (en) Treatment of pediatric acute lymphoblastic leukemia
HK1215258B (en) Treatment of pediatric acute lymphoblastic leukemia
HK1158667B (en) Treatment of pediatric acute lymphoblastic leukemia
HK1220705B (en) Treatment of acute lymphoblastic leukemia
HK1158668B (en) Treatment of acute lymphoblastic leukemia

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20141024

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 15TH ANNIV.) - STANDARD

Year of fee payment: 15

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241024

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241024

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241024

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 16TH ANNIV.) - STANDARD

Year of fee payment: 16

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251022

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251022